These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 20507310)

  • 1. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
    Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
    Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
    Diedrich B; Ringdén O; Watz E; Shanwell A
    Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
    van Rhenen DJ; Gulliksson H; Cazenave JP; Pamphilon D; Davis K; Flament J; Corash L
    Transfus Med; 2004 Aug; 14(4):289-95. PubMed ID: 15285725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
    Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J
    Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
    Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
    Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
    van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
    Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.
    Cid J; Escolar G; Lozano M
    Vox Sang; 2012 Nov; 103(4):322-30. PubMed ID: 22563850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
    Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
    Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarify the negatives of the MIRASOL noninferiority trial.
    Strauss RG
    Transfusion; 2011 Jun; 51(6):1361-2; author reply 1362-4. PubMed ID: 21658043
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
    Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
    Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
    Lozano M; Galan A; Mazzara R; Corash L; Escolar G
    Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.
    Heddle NM; Cook RJ; Blajchman MA; Barty RL; Sigouin CS; Boye DM; Nelson EJ; Kelton JG
    Transfusion; 2005 Jun; 45(6):896-903. PubMed ID: 15934987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacterial contamination: should it be detected or inactivated?].
    Cazenave JP
    Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.
    Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L
    Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol).
    Azuma H; Hirayama J; Akino M; Miura R; Kiyama Y; Imai K; Kasai M; Koizumi K; Kakinoki Y; Makiguchi Y; Kubo K; Atsuta Y; Fujihara M; Homma C; Yamamoto S; Kato T; Ikeda H
    Transfusion; 2009 Feb; 49(2):214-8. PubMed ID: 18798806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
    Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
    Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.